Dr. Coutre Discusses Challenges With CAR T-Cell Therapy in ALL

Video

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia.

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Tisagenlecleucel (Kymriah), the first FDA-approved CAR T-cell therapy, is approved for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse. However, it is not approved in adults, and Coutre says that it is not yet known whether CAR T-cell therapy will be used with a curative intent or as a bridge to transplant.

In pediatric patients, investigators are looking to move tisagenlecleucel to earlier lines of therapy. But, if issues with toxicities can be better defined, Coutre says that CAR T-cell therapy may be appropriate for some patients above the current indicated age range.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,